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Nonstandard Abbreviations and Acronyms 
CMR: cardiac magnetic resonance  
CPEx: cardiopulmonary exercise test 
HCM: hypertrophic cardiomyopathy 
ICD: implantable cardioverter defibrillator 
LHON: Leber hereditary optic neuropathy 
LVH: left ventricular hypertrophy  
MLVWT: maximum LV wall thickness 
MELAS: Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes 
mtDNA: mitochondrial DNA 
WES: whole exome sequencing  




Mitochondrial cytopathies caused by mitochondrial DNA(mtDNA) mutations have an estimated 
prevalence of 1/5,000 adults
1
. Cardiac manifestations are common (up to 40%) and include 
hypertrophic cardiomyopathy(HCM). Some mtDNA mutations 
(e.g.m.3243A>G,m.8344A>G,m.4300A>G) are well-recognised causes of cardiomyopathy  and 
may occur as part of a multi-organ syndrome, such as MELAS(Mitochondrial 
Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes), or as the only manifestation.  
Up to 60% of HCM probands have no detectable causal mutations, while the prevalence 
of pathogenic mtDNA variants in large HCM cohorts has not previously been determined. We 
hypothesised that the presence of mtDNA mutations might account for a proportion of genotype-
negative cases and applied a workflow to reliably identify mtDNA variants from whole exome 
sequencing(WES) data. 
The study population and clinical evaluation have been previously described
2
. All 
patients provided written informed consent and the study had ethics committee 
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annotation were previously reported
2,3
. Mitochondrial variants with read-depth≥10x and 
heteroplasmy level≥10% were chosen for validation and confirmation using whole mtDNA next-
generation sequencing. Data that support the findings are available upon request. 
The cohort comprised 770 unrelated HCM patients(67% males, age 49.3±15.9 years at 
diagnosis); 33% had candidate variants in sarcomeric genes robustly associated with HCM. Six-
hundred-and-fifty-nine samples passed quality control with called mitochondrial variants (mean 
depth 20.2).  
The MT-TL1 m.3243A>G mutation, a well-recognised cause of HCM, was detected at 
heteroplasmic levels in two probands(0.4% of sarcomere-negatives) in whom a primary 
mitochondrial disease diagnosis had not previously been suspected. A third proband was 
homoplasmic for MT-ND1 m.3460G>A, a pathogenic variant associated with Leber hereditary 
optic neuropathy(LHON). The patients did not harbour any other candidate variants in nuclear-
encoded HCM genes.  
Proband 1 was a female who presented at 35 years due to breathlessness and chest pain. 
Past medical history included well-controlled hypertension diagnosed at 19 years, bilateral 
deafness attributed to parotiditis, repeat miscarriages(five), and gestational diabetes. Family 
history was unremarkable. Electrocardiogram showed left ventricular hypertrophy (LVH) and T 
wave inversion; echocardiography revealed symmetric/concentric LVH -maximum LV wall 
thickness(MLVWT) 16mm; cardiac magnetic resonance(CMR) showed extensive fibrosis with 
subepicardial distribution (Figure 1A). Cardiopulmonary exercise test(CPEx) revealed a low 
peak oxygen consumption of 18ml/min/kg (53% predicted) and anaerobic threshold of 33%. The 
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Proband 2 was a male who presented at 61 years with heart failure and atrial fibrillation. 
Past medical history included hypertension (well-controlled on medication), diabetes mellitus 
complicated by retinopathy, and multiple strokes. Family history was uninformative. ECG 
showed atrial fibrillation and left bundle branch block.  Echocardiography revealed severe LV 
systolic dysfunction and septal hypertrophy(14mm); relative wall thickness 0.46 (concentric 
remodelling). CMR showed extensive circumferential mid-myocardial/subepicardial 
enhancement (Figure 1B) with an LV ejection fraction 33%. Creatine kinase was mildly 
increased at 340 IU/L. A dual chamber implantable cardioverter defibrillator (ICD) with 
resynchronization therapy was implanted at 72 years and an appropriate shock occurred 3 
months thereafter. He died at 74 years due to decompensated heart failure. The m.3243A>G 
mutation was identified at 11% load.  
Proband 3 was a male who presented at 39 years with chest pain and breathlessness. ECG 
showed marked LVH, inferolateral T wave inversion(Figure 1C).  CMR revealed septal-apical 
LVH with MLVWT 26mm and extensive patchy enhancement, in the anterolateral wall and 
septum(Figure 1C). Nonsustained ventricular tachycardia was detected and an ICD was 
implanted. During follow-up, LHON was diagnosed in a maternal aunt and cousin; his mother 
was known to carry the mutation with no clinical manifestations. He had an ophthalmologic 
assessment with no features of optic neuropathy. The m.3460G>A was detected at homoplasmic 
levels in blood. 
In retrospect, both patients harbouring the m.3243A>G mutation had features consistent 
with a non-sarcomeric aetiology. Proband 1 had multiple miscarriages, gestational diabetes, and 
hearing loss, in addition to limited performance on the CPEx; Proband 2 exhibited systolic 
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unusual for sarcomeric HCM but is consistent with findings in one other case series describing 
CMR findings in patients with mitochondrial mutations
4
.  
Sequencing off-target captured mtDNA from exome data has been described previously 
and refined in-house
3
. This methodology had never been applied to screen a HCM cohort for 
pathogenic mtDNA variants. A previous study utilising whole-genome sequencing(WGS) 
detected the pathogenic m.4300A>G variant in 1/46 genotype-negative HCM patients
5
. The 
coverage achieved with WGS is higher, but most clinical and research cohorts are studied using 
WES.  
HCM caused by mtDNA mutations is characterised by ventricular arrhythmia, 
conduction disease and evolution to systolic dysfunction. A thorough assessment for extra-
cardiac manifestations is crucial if mitochondrial disease is suspected. The detection of 
pathogenic mtDNA variants has significant impact for the genetic counselling and management 
of the proband and their relatives.  
Iterative reanalysis of WES data for mtDNA mutations increases the yield of genetic 
testing in HCM, and should therefore be considered in genetically undiagnosed HCM cohorts.  
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supported by a Medical Research Council Clinician Scientist Fellowship (MR/S002065/1). 
RDSP and MGH receive funding from a Medical Research Council strategic award to establish 




This article is published in its accepted form; it has not been copyedited and has not appeared in an issue of the journal. Preparation for 
inclusion in an issue of Circulation: Genomic and Precision Medicine involves copyediting, typesetting, proofreading, and author review, 
which may lead to differences between this accepted version of the manuscript and the final published version. 







1. Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, Alston CL, Feeney C, Horvath R, 
Yu-Wai-Man P, Chinnery PF, et al. Prevalence of nuclear and mitochondrial DNA mutations 
related to adult mitochondrial disease. Ann Neurol. 2015;77:753-9. 
 
2. Lopes LR, Futema M, Akhtar MM, Lorenzini M, Pittman A, Syrris P and Elliott PM. 
Prevalence of TTR variants detected by whole-exome sequencing in hypertrophic 
cardiomyopathy. Amyloid. 2019;26:243-247. 
 
3. Poole OV, Pizzamiglio C, Murphy D, Falabella M, Macken WL, Bugiardini E, Woodward 
CE, Labrum R, Efthymiou S, Salpietro V, et al. Mitochondrial DNA analysis from exome 
sequencing data improves the diagnostic yield in neurological diseases. Ann Neurol. 2021 Mar 
11. doi: 10.1002/ana.26063. Online ahead of print. 
 
4. Florian A, Ludwig A, Stubbe-Drager B, Boentert M, Young P, Waltenberger J, Rosch S, 
Sechtem U and Yilmaz A. Characteristic cardiac phenotypes are detected by cardiovascular 
magnetic resonance in patients with different clinical phenotypes and genotypes of mitochondrial 
myopathy. J Cardiovasc Magn Reson. 2015;17:40. 
 
5. Bagnall RD, Ingles J, Dinger ME, Cowley MJ, Ross SB, Minoche AE, Lal S, Turner C, Colley 
A, Rajagopalan S, et al. Whole Genome Sequencing Improves Outcomes of Genetic Testing in 






Figure 1A. Electrocardiogram (ECG) and cardiac magnetic resonance (CMR) images (from left 
to right, 4 chamber, short axis and 2 chamber views; upper row end-diastolic cine images, lower 
row late gadolinium enhancement images) for Proband 1, harbouring the m.3243A>G mutation 
in MT-TL1.  ECG shows T wave inversion V2 to V6, DI, DII and aVL. CMR shows concentric 
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apical anterior, lateral and inferior walls. B. Cardiac magnetic resonance (CMR) images (from 
left to right, 4 chamber and mid short axis views; upper row end-diastolic cine images, lower row 
late gadolinium enhancement images), for Proband 2 harbouring the m.3243A>G mutation in 
MT-TL1, showing extensive circumferential mid-myocardial/subepicardial enhancement and 
localized inferior septum hypertrophy (14mm); relative wall thickness was 0,46, indicative of 
concentric remodelling. C. Electrocardiogram (ECG) and cardiac magnetic resonance (CMR) 
images (from left to right, 4 chamber and 2 chamber views; upper row end-diastolic cine images 
and lower row late gadolinium enhancement images) for Proband 3, homoplasmic for the 
pathogenic m.3460G>A variant in ND1. ECG shows left ventricular hypertrophy and deep T 
wave inversion V3 to V6, DI, DII, aVL and aVF. CMR shows septal and apical LVH and 
extensive patchy enhancement, mainly in the anterolateral wall and septum. 
